APA (7th ed.) Citation

CS, S., P, C., H, S., DZ, X., D, C., S, V., . . . B, W. (2021). Atezolizumab and Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: Pharmacokinetic and Safety Assessments Based on Hepatic Impairment Status and Geographic Region. Liver cancer, 10(5), 485. https://doi.org/10.1159/000515817

Chicago Style (17th ed.) Citation

CS, Shemesh, Chan P, Shao H, Xu DZ, Combs D, Vadhavkar S, Bruno R, and Wu B. "Atezolizumab and Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: Pharmacokinetic and Safety Assessments Based on Hepatic Impairment Status and Geographic Region." Liver Cancer 10, no. 5 (2021): 485. https://doi.org/10.1159/000515817.

MLA (9th ed.) Citation

CS, Shemesh, et al. "Atezolizumab and Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: Pharmacokinetic and Safety Assessments Based on Hepatic Impairment Status and Geographic Region." Liver Cancer, vol. 10, no. 5, 2021, p. 485, https://doi.org/10.1159/000515817.